Latest treatment of multiple sclerosis Stories
National MS Society Leads the Way in Cutting Edge Research to Stop MS, Restore Function and End MS Forever NEW YORK, Dec. 20, 2010 /PRNewswire-USNewswire/ -- Exciting advances were made in 2010 in virtually every field of MS research.
EXTON, Pa., Dec. 6, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that surveyed neurologists indicate that their initial trial of Novartis's Gilenya has been hampered by potential safety / tolerability concerns and monitoring requirements.
BURLINGTON, Mass., Dec. 1, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that less than 30 percent of surveyed relapsing-remitting multiple sclerosis (MS) patients in the U.S.
ANN ARBOR, Mich., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc.
EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US.
PARIS, October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).
PHILADELPHIA, Oct. 12 /PRNewswire/ -- MS-Leaders.org, a medical education portal from Medical Logix, LLC, is inviting neurologists and multiple sclerosis treating clinicians to participate in an exciting medical education platform designed to share best practices in the management of MS patients.
SILVER SPRING, Md., Sept. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).
EAST HANOVER, N.J., Sept.
WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists have low awareness of Novartis/Mitsubishi Tanabe's FTY-720 (Gilenia) among the surveyed oral emerging therapies for the treatment of multiple sclerosis (MS).
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.